Jing Xie

Senior Vice President, Microport Orthopaedics

Jing Xie is the Senior Vice President, Global Regulatory and Clinical Affairs at MicroPort Orthopedics Inc. She joined MicroPort in September 2021 with over 20 years' experience in leading global teams and developing and executing clinical and regulatory strategies to accelerate market access and market development. Prior to joining MicroPort, Jing held multiple executive level positions, including Sr. Vice President, Global Clinical and Medical Affairs at Smith and Nephew, Vice President, Clinical, Regulatory and Office of Medical Affairs at Medtronic, Vice President, Clinical Affairs, Medical Device Innovation Consortium, Vice President, Global Clinical Affairs at Zimmer Biomet, and Vice President, Global Clinical Research at Biomet. She received her Bachelor of Science in Analytical Chemistry from Xiamen University, her Master of Science in Chemistry and Ph.D. in Materials Science from University of Alabama, and her Master of Science in Computer Science from Purdue University. She also attended the Global Leadership Program at the University of Notre Dame Mendozza College of Business.

David Lawson

Policy lead for Medical Technology & Innovation with responsibility for the implementation of the Government's inaugural Medical Technology Strategy published February 2023 and commitments under the 10 Year Health Plan and Life Science Sector Plan published July 2025. Key initiatives include: Design for Life programme, Innovative Devics Access Pathway, Rules Based Pathway, Value Based Procurement guidance, MedTech Compass comparison system, National Product Information Management system, Reform of £1.6bn Part IX Drug Tariff.  Former Chief Procurement Officer at Guy's and St Thomas' NHS Foundation Trust – a position held for 21 years – and double winner of the Supply Chain Excellence Award in 2008 and 2021.

Salma Husain

Senior Benefit Risk Evaluation Assessor - Musculoskeletal, Trauma and Cosmetic , Medicines and Healthcare products Regulatory Agency (MHRA)

Salma is a Senior Benefit Risk Evaluation Assessor within the Musculoskeletal, Trauma and Cosmetics team at the Medicines and Healthcare products Regulatory Agency (MHRA). With over 13 years' experience of EU & UK medical device regulations, she's led investigations of orthopaedic implant outlier devices, managed manufacturer Field Safety Corrective Actions and worked with key clinical stakeholders such as the orthopaedic Expert Advisory Group to issue updated advice for people implanted with metal-on-metal hip arthroplasties. Outside of orthopaedics, Salma managed the MHRA clinical Investigation process working with other healthcare agencies to pilot and deliver streamlined review processes; enabling faster access to innovative devices, and led the Agency's investigation into BIA-ALCL, a rare form of non-Hodgkin's lymphoma associated with certain implants. Salma also spent three years at BSI conducting technical reviews and managing the conformity assessment process for clients from onboarding, to preparing recommendations for CE and UKCA certification and managing the post market activities.   

Salma is also a member of the Implants for Surgery International Standards Committee, reviewing the standards with a special interest in ensuring information for patients & surgeons contain the clear and relevant information regarding the risks and benefits of the implantable medical devices.